MCID: GNG004
MIFTS: 53

Ganglioglioma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Ganglioglioma

MalaCards integrated aliases for Ganglioglioma:

Name: Ganglioglioma 12 73 20 58 54 6 44 15 39 17 70
Childhood Ganglioglioma 12 6 70
Adult Ganglioglioma 12 70
Mixed Cell Tumors Containing Both Neural Ganglionic Cells and Neural Glial Cell Components 20
Cns Ganglioglioma 12

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:5078
MeSH 44 D018303
SNOMED-CT 67 87191000119100
UMLS via Orphanet 71 C0206716
Orphanet 58 ORPHA251949
UMLS 70 C0206716 C1332202 C1332969

Summaries for Ganglioglioma

GARD : 20 A ganglioglioma is a rare type of brain tumor, accounting for approximately 1% of all brain tumors. Gangliogliomas occur when a single cell in the brain starts to divide into more cells, forming a tumor. This can occur when the cell randomly acquires changes ( mutations ) in genes that regulate how a cell divides. Most gangliogliomas grow slowly and are considered benign. However, up to 10% of gangliogliomas may grow more rapidly and become malignant, meaning the tumor affects the surrounding brain tissue. The main treatment for ganglioglioma is removal of the entire tumor during surgery. If the entire tumor is not removed, it has the potential to recur and may require additional surgery or treatments, such as radiation therapy or chemotherapy. Unfortunately, because gangliogliomas are quite rare, there is limited information to show that radiation therapy or chemotherapy are effective treatments for this condition.

MalaCards based summary : Ganglioglioma, also known as childhood ganglioglioma, is related to anaplastic ganglioglioma and desmoplastic infantile ganglioglioma, and has symptoms including seizures An important gene associated with Ganglioglioma is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Glioma and Integrated Breast Cancer Pathway. The drugs Trametinib and Dabrafenib have been mentioned in the context of this disorder. Affiliated tissues include brain, temporal lobe and spinal cord, and related phenotypes are Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation and behavior/neurological

Disease Ontology : 12 A cell type benign neoplasm that has material basis in glial-type cells.

Wikipedia : 73 Ganglioglioma is a rare, slow-growing primary central nervous system (CNS) tumor which most frequently... more...

Related Diseases for Ganglioglioma

Diseases related to Ganglioglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 469)
# Related Disease Score Top Affiliating Genes
1 anaplastic ganglioglioma 32.9 NES GFAP
2 desmoplastic infantile ganglioglioma 32.2 SYP MYCN GFAP BRAF
3 gangliocytoma 31.6 TH SYP PVALB GFAP ENO2
4 rhabdoid cancer 30.6 TP53 SYP SMARCB1
5 malignant astrocytoma 30.4 TP53 S100B NF1 NES H3-3A GFAP
6 pilocytic astrocytoma 30.3 TP53 SYP S100B NF1 NES GFAP
7 oligodendroglioma 30.3 TP53 SYP S100B NF1 GFAP ENO2
8 anaplastic ependymoma 30.3 SYP S100B GFAP
9 cellular ependymoma 30.3 SYP S100B NES GFAP
10 anaplastic astrocytoma 30.3 TP53 NES H3-3A GFAP
11 neurofibroma 30.3 TP53 SYP S100B NF1
12 hydrocephalus 30.3 TP53 SYP SMARCB1 S100B NES GFAP
13 extraventricular neurocytoma 30.3 SYP GFAP
14 high grade glioma 30.2 TP53 NF1 NES H3-3A GFAP BRAF
15 pilocytic astrocytoma of cerebellum 30.2 NF1 BRAF
16 glioblastoma 30.1 TP53 NF1 NES MYCN H3-3A GFAP
17 central neurocytoma 30.1 SYP NES MAP2 GFAP ENO2 CHGA
18 chiari malformation 30.1 SYP MAP2 GFAP
19 orbital cancer 30.1 SYP NF1 ENO2
20 cowden syndrome 30.1 TSC2 TSC1 TP53 NF1
21 obstructive hydrocephalus 30.1 TSC1 SYP NF1 GFAP ENO2
22 cerebellar liponeurocytoma 30.1 SYP MAP2 ENO2
23 hemimegalencephaly 30.0 TSC2 MAP2 GFAP
24 tanycytic ependymoma 30.0 SYP GFAP
25 traumatic brain injury 30.0 S100B GFAP ENO2
26 rosette-forming glioneuronal tumor 30.0 SYP S100B MAP2
27 mature teratoma 30.0 TP53 SYP ENO2 BRAF
28 cystic teratoma 30.0 TP53 SYP GFAP ENO2
29 optic nerve glioma 29.9 S100B NF1 NES GFAP ENO2
30 benign teratoma 29.9 TP53 SYP ENO2 CHGA
31 peutz-jeghers syndrome 29.9 TSC2 TSC1 TP53
32 benign ependymoma 29.9 TSC2 TSC1 SYP NF1 GFAP
33 adenoma 29.9 TSC1 TP53 SYP CHGA BRAF
34 hemangioblastoma 29.9 SYP S100B GFAP ENO2
35 inflammatory myofibroblastic tumor 29.8 TP53 S100B ENO2
36 meningioma, familial 29.8 TP53 SYP SMARCB1 S100B NF1 GFAP
37 pleomorphic xanthoastrocytoma 29.8 TP53 SYP SMARCB1 S100B MAP2 H3-3A
38 dysembryoplastic neuroepithelial tumor 29.7 SYP S100B NES MAP2 GRIN1 GFAP
39 diffuse midline glioma, h3 k27m-mutant 29.7 TP53 NES MYCN H3-3A
40 rhabdoid meningioma 29.7 SYP SMARCB1 GFAP ENO2 BRAF
41 neurilemmoma 29.7 SMARCB1 S100B NF1 NES GFAP ENO2
42 basal cell nevus syndrome 29.7 TP53 SMARCB1 NF1 MYCN
43 subependymoma 29.6 TSC2 SYP NES GFAP ENO2 CHGA
44 nervous system disease 29.6 TP53 TH NES MYCN GFAP
45 hemangioma 29.5 TSC2 TSC1 TP53 SYP ENO2 CHGA
46 atypical teratoid rhabdoid tumor 29.5 TP53 SYP SMARCB1 S100B MYCN H3-3A
47 cerebellum cancer 29.5 TP53 SYP NF1 MYCN GFAP ENO2
48 ganglioneuroblastoma 29.5 TH SYP S100B MYCN ENO2
49 giant cell glioblastoma 29.5 TP53 SYP MYCN H3-3A GFAP BRAF
50 west syndrome 29.4 TSC2 TSC1 TH PVALB

Graphical network of the top 20 diseases related to Ganglioglioma:



Diseases related to Ganglioglioma

Symptoms & Phenotypes for Ganglioglioma

UMLS symptoms related to Ganglioglioma:


seizures

GenomeRNAi Phenotypes related to Ganglioglioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 BRAF ENO2 MYCN TSC1 TSC2

MGI Mouse Phenotypes related to Ganglioglioma:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.45 BRAF DCX ENO2 GFAP GRIN1 MAP2
2 growth/size/body region MP:0005378 10.36 BRAF CHGA DCX ENO2 GFAP GRIN1
3 mortality/aging MP:0010768 10.35 BRAF CHGA DCX GFAP GRIN1 MAP2
4 cardiovascular system MP:0005385 10.31 BRAF CHGA GFAP GRIN1 MYCN NF1
5 nervous system MP:0003631 10.31 BRAF CHGA DCX ENO2 GFAP GRIN1
6 cellular MP:0005384 10.3 BRAF ENO2 GFAP GRIN1 MYCN NF1
7 muscle MP:0005369 10.11 BRAF CHGA GFAP MYCN NF1 PVALB
8 liver/biliary system MP:0005370 10.1 BRAF MYCN NF1 SMARCB1 TH TP53
9 normal MP:0002873 10.06 BRAF GFAP GRIN1 MYCN NF1 PVALB
10 neoplasm MP:0002006 9.98 BRAF NF1 SMARCB1 TH TP53 TSC1
11 no phenotypic analysis MP:0003012 9.91 CHGA GRIN1 MYCN NSD1 PVALB TH
12 renal/urinary system MP:0005367 9.91 BRAF CHGA MYCN NF1 PVALB TH
13 reproductive system MP:0005389 9.9 BRAF CHGA DCX GRIN1 MAP2 MYCN
14 respiratory system MP:0005388 9.56 BRAF ENO2 GRIN1 MYCN NF1 TH
15 vision/eye MP:0005391 9.32 BRAF GFAP GRIN1 MYCN NF1 PVALB

Drugs & Therapeutics for Ganglioglioma

Drugs for Ganglioglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 26)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trametinib Approved Phase 4 871700-17-3 11707110
2
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
3 Protein Kinase Inhibitors Phase 4
4
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
5
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
6
Dimethyl sulfoxide Approved, Vet_approved Phase 2 67-68-5 679
7 Antimitotic Agents Phase 2
8 Tubulin Modulators Phase 2
9 Antioxidants Phase 2
10 Protective Agents Phase 2
11
Irinotecan Approved, Investigational Phase 1 97682-44-5, 100286-90-6 60838
12
Bevacizumab Approved, Investigational Phase 1 216974-75-3
13
Gemcitabine Approved Phase 1 95058-81-4 60750
14
Lenograstim Approved, Investigational Phase 1 135968-09-1
15
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
16 Angiogenesis Inhibitors Phase 1
17 topoisomerase I inhibitors Phase 1
18 Antineoplastic Agents, Immunological Phase 1
19 Immunosuppressive Agents Phase 1
20 Anti-Infective Agents Phase 1
21 Antimetabolites Phase 1
22 Antiviral Agents Phase 1
23 Immunologic Factors Phase 1
24 Antirheumatic Agents Phase 1
25 Anesthetics Phase 1
26 Alkylating Agents Phase 1

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
2 Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG) Recruiting NCT02684058 Phase 2 dabrafenib;trametinib;Carboplatin with vincristine
3 A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG) Recruiting NCT03919071 Phase 2 Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide
4 A Phase II Study of Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation: An Assessment of Long Term Neurocognitive, Neuroendocrine Adn Ototoxicity Outcomes Active, not recruiting NCT01288235 Phase 2
5 Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors, A Feasibility Study Completed NCT01999270 Phase 1 Irinotecan;Bevacizumab
6 Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma Recruiting NCT03434262 Phase 1 Gemcitabine;ribociclib;sonidegib;trametinib
7 A Phase I Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2, a Genetically Engineered HSV-1 Virus, and Immunomodulation With Cyclophosphamide Recruiting NCT03152318 Phase 1 rQNestin;Cyclophosphamide
8 Astrocytoma / Desmoplastic Gamliogliomes (DIA / DIG) - Study of the French Cohort of the Last 20 Years : Clinical, Anatomopathological, Molecular and Radiological Charactersics Unknown status NCT03115164
9 Intraoperative Fluorescence of Gangliogliomas and Neuroepithelial Dysembryoplastic Tumors Completed NCT03970785
10 Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology Recruiting NCT04648462
11 A Phase II Study of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma Recruiting NCT04065776
12 Defining Personal and Communal Aspects of Social Determinants of Health in Glioblastoma Population Recruiting NCT03900689

Search NIH Clinical Center for Ganglioglioma

Cochrane evidence based reviews: ganglioglioma

Genetic Tests for Ganglioglioma

Anatomical Context for Ganglioglioma

MalaCards organs/tissues related to Ganglioglioma:

40
Brain, Temporal Lobe, Spinal Cord, Pituitary, Pineal, Cerebellum, Lung

Publications for Ganglioglioma

Articles related to Ganglioglioma:

(show top 50) (show all 1107)
# Title Authors PMID Year
1
The reelin pathway components disabled-1 and p35 in gangliogliomas--a mutation and expression analysis. 54 61
15175076 2004
2
Mutational analysis of TSC1 and TSC2 genes in gangliogliomas. 54 61
11437991 2001
3
Tuberin expression in ganglioglioma. 61 54
10808554 2000
4
alpha-Synuclein is expressed in a variety of brain tumors showing neuronal differentiation. 54 61
10672322 2000
5
Synaptophysin staining for ganglioglioma. 61 54
10219424 1999
6
The significance of immunocytochemical markers, synaptophysin and neurofilaments in diagnosis of ganglioglioma. 54 61
10581850 1999
7
Mixed dysembryoplastic neuroepithelial tumor and ganglioglioma. 61 54
9650758 1998
8
Immunohistochemical expression of tyrosine kinase (Trk) receptor proteins in mature neuronal cell tumors of the central nervous system. 54 61
9625303 1998
9
Synaptophysin staining in normal brain: importance for diagnosis of ganglioglioma. 54 61
9591724 1998
10
Pleomorphic xanthoastrocytoma with gangliogliomatous component. 54 61
9521020 1997
11
Rapid growth of an optic nerve ganglioglioma in a patient with neurofibromatosis 1. 61 54
8637690 1996
12
Central nervous system gangliogliomas. Part 1: Pathology. 54 61
8246054 1993
13
Immunohistochemistry of synapsin I and synaptophysin in human nervous system and neuroendocrine tumors. Applications in diagnostic neuro-oncology. 54 61
8287627 1993
14
Parvalbumin and calbindin D-28K immunoreactivity in central ganglioglioma and dysplastic gangliocytoma of the cerebellum. Report of two cases. 61 54
8416231 1993
15
A clinicopathologic and immunomorphologic study of 13 cases of ganglioglioma. 61 54
1913457 1991
16
Epizootic neoplasia in a managed population of Atlantic bumper fish, Chloroscombrus chrysurus (Osteichthyes: Carangidae), at a public aquarium. 61
33348452 2021
17
Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib. 61
33211390 2021
18
Anaplasic ganglioglioma: Cervical-dorso-lumbar leptomeningeal dissemination. About a case. 61
32265155 2021
19
Gangliogliomas in the pediatric population. 61
32989499 2021
20
Clinical Characteristics of BRAF V600E Gene Mutation in Patients of Epilepsy-Associated Brain Tumor: a Meta-analysis. 61
33791912 2021
21
Clinical and Neuroimaging Features of Magnetic Resonance-Guided Stereotactic Laser Ablation for Newly Diagnosed and Recurrent Pediatric Brain Tumors: A Single Institutional Series. 61
33722713 2021
22
Can we use intraoperative high-frequency oscillations to guide tumor-related epilepsy surgery? 61
33617688 2021
23
Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile. 61
33051600 2021
24
Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with BRAF p.T599dup mutation. 61
33637608 2021
25
Rare Activating BRAF Alteration Involving the β3-αC Kinase Domain in Ganglioglioma. 61
33611593 2021
26
Pituitary stalk gangliogliomas: Case report and literature review. 61
33340839 2021
27
Multiple Intraspinal Gangliogliomas in a Child With Neurofibromatosis Type 1: Case Report and Literature Review. 61
33448717 2021
28
Cerebrospinal fluid liquid biopsy for detecting somatic mosaicism in brain. 61
33738444 2021
29
Morphological diversity in H3G34-mutant high-grade gliomas: Ganglionic and epithelioid features. 61
32631482 2021
30
Giant Cerebellar Ganglioglioma Mimicking a Pilocytic Astrocytoma. 61
33500838 2021
31
Desmoplastic infantile astrocytoma and ganglioglioma: a series of 12 patients treated at a single institution. 61
33507362 2021
32
Biology and grading of pleomorphic xanthoastrocytoma-what have we learned about it? 61
32619305 2021
33
Serum cytokines in astrocytic brain tumors: a prospective study. 61
33349075 2020
34
Infantile and Noninfantile Desmoplastic Astrocytoma and Ganglioglioma: Only Different Age of Onset? 61
32822952 2020
35
Conditional reprograming culture conditions facilitate growth of lower grade glioma models. 61
33258947 2020
36
Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. 61
33242424 2020
37
Seizure-outcome after surgery of low-grade epilepsy associated neuro-epithelial tumors. 61
33320468 2020
38
Primary Anaplastic Ganglioglioma of the Temporal Lobe With Brainstem Involvement: A Case Report and Literature Review. 61
33447489 2020
39
BRAF V600E-Mutated Ganglioglioma of the Optic Pathway: A Case Report and Review of the Literature. 61
33394641 2020
40
Oligodendroglioma with ganglioglioma like differentiation: management and prognostic implications. Is a WHO classification update required? 61
32951414 2020
41
Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma. 61
31985841 2020
42
Intramedullary spinal cord ganglioglioma: Case report and comparative literature review. 61
33092982 2020
43
Atypical teratoid/rhabdoid tumor with ganglioglioma-like differentiation: Case report. 61
33071203 2020
44
Diagnostic accuracy for the epileptogenic zone detection in focal epilepsy could be higher in FDG-PET/MRI than in FDG-PET/CT. 61
33063184 2020
45
Low-grade epilepsy-associated tumour management with or without presurgical evaluation: a multicentre, retrospective, observational study of postsurgical epilepsy outcome. 61
32985985 2020
46
Role of Long-Term Vestibular Rehabilitation in a Patient with Posterior Fossa Tumor: A Case Report with 2 Years of Follow-Up. 61
32915776 2020
47
Spinal anaplastic ganglioglioma. 61
32969749 2020
48
Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma. 61
32788236 2020
49
Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm. 61
32648041 2020
50
Risk stratification in pediatric low-grade glioma and glioneuronal tumor treated with radiation therapy: an integrated clinicopathologic and molecular analysis. 61
32052049 2020

Variations for Ganglioglioma

ClinVar genetic disease variations for Ganglioglioma:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 BRAF NM_004333.6(BRAF):c.1794_1796dup (p.Thr599dup) Duplication Pathogenic 162793 rs727502902 GRCh37: 7:140453138-140453139
GRCh38: 7:140753338-140753339
2 NF1 NM_001042492.2(NF1):c.6852_6855del (p.Tyr2285fs) Deletion Likely pathogenic 216866 rs1555535032 GRCh37: 17:29665752-29665755
GRCh38: 17:31338734-31338737
3 BAP1 NM_004656.4(BAP1):c.1833G>C (p.Glu611Asp) SNV Uncertain significance 620598 rs771494475 GRCh37: 3:52437211-52437211
GRCh38: 3:52403195-52403195

Cosmic variations for Ganglioglioma:

9 (show all 42)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149315872 ZFHX3 central nervous system,brain,other,ganglioglioma c.10376C>T p.P3459L 16:72787900-72787900 3
2 COSM102040939 ZFHX3 central nervous system,brain,other,ganglioglioma c.7634C>T p.P2545L 16:72787900-72787900 3
3 COSM87290663 ZFHX3 central nervous system,brain,other,ganglioglioma c.10376C>T p.P3459L 16:72787900-72787900 3
4 COSM102656129 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 3
5 COSM89046819 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 3
6 COSM105514140 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 3
7 COSM94463526 NF2 central nervous system,brain,other,neoplasm c.452A>G p.Y151C 22:29655652-29655652 3
8 COSM102848205 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 3
9 COSM93474794 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 3
10 COSM89067962 NF2 central nervous system,brain,other,neoplasm c.326A>G p.Y109C 22:29655652-29655652 3
11 COSM105111282 NF2 central nervous system,brain,other,neoplasm c.447+13367A>G p.? 22:29655652-29655652 3
12 COSM95502154 NF2 central nervous system,brain,other,neoplasm c.449A>G p.Y150C 22:29655652-29655652 3
13 COSM92446479 NF2 central nervous system,brain,other,neoplasm c.326A>G p.Y109C 22:29655652-29655652 3
14 COSM133282459 IDH2 central nervous system,temporal lobe,other,ganglioglioma c.336G>A p.W112* 15:90088629-90088629 3
15 COSM136793306 IDH2 central nervous system,temporal lobe,other,ganglioglioma c.208-127G>A p.? 15:90088629-90088629 3
16 COSM89230121 IDH2 central nervous system,temporal lobe,other,ganglioglioma c.492G>A p.W164* 15:90088629-90088629 3
17 COSM90465359 IDH1 central nervous system,brain,other,neoplasm c.395G>A p.R132H 2:208248388-208248388 3
18 COSM112752230 IDH1 central nervous system,brain,other,neoplasm c.395G>A p.R132H 2:208248388-208248388 3
19 COSM103033757 IDH1 central nervous system,brain,other,neoplasm c.395G>A p.R132H 2:208248388-208248388 3
20 COSM103033796 IDH1 central nervous system,brain,other,neoplasm c.394C>T p.R132C 2:208248389-208248389 3
21 COSM103034325 IDH1 central nervous system,brain,other,neoplasm c.394C>A p.R132S 2:208248389-208248389 3
22 COSM112752272 IDH1 central nervous system,brain,other,neoplasm c.394C>T p.R132C 2:208248389-208248389 3
23 COSM90465396 IDH1 central nervous system,brain,other,neoplasm c.394C>T p.R132C 2:208248389-208248389 3
24 COSM90466087 IDH1 central nervous system,brain,other,neoplasm c.394C>A p.R132S 2:208248389-208248389 3
25 COSM90465733 IDH1 central nervous system,brain,other,neoplasm c.394C>G p.R132G 2:208248389-208248389 3
26 COSM112752610 IDH1 central nervous system,brain,other,neoplasm c.394C>G p.R132G 2:208248389-208248389 3
27 COSM112752921 IDH1 central nervous system,brain,other,neoplasm c.394C>A p.R132S 2:208248389-208248389 3
28 COSM112752563 IDH1 central nervous system,brain,other,neoplasm c.395G>T p.R132L 2:208248388-208248388 3
29 COSM90465675 IDH1 central nervous system,brain,other,neoplasm c.395G>T p.R132L 2:208248388-208248388 3
30 COSM103034038 IDH1 central nervous system,brain,other,neoplasm c.394C>G p.R132G 2:208248389-208248389 3
31 COSM103034000 IDH1 central nervous system,brain,other,neoplasm c.395G>T p.R132L 2:208248388-208248388 3
32 COSM93220513 FOXO3 central nervous system,brain,other,neoplasm c.583A>T p.K195* 6:108561791-108561791 3
33 COSM102860866 FOXO3 central nervous system,brain,other,neoplasm c.583A>T p.K195* 6:108561791-108561791 3
34 COSM130561817 C11orf65 central nervous system,brain,other,ganglioglioma c.641-8418C>G p.? 11:108317489-108317489 3
35 COSM131103045 BRCA2 central nervous system,brain,other,ganglioglioma c.9085G>A p.A3029T 13:32379881-32379881 3
36 COSM99025171 BRCA2 central nervous system,brain,other,ganglioglioma c.9085G>A p.A3029T 13:32379881-32379881 3
37 COSM149385292 BRAF central nervous system,brain,other,ganglioglioma c.1919T>A p.V640E 7:140753336-140753336 3
38 COSM88803061 BRAF central nervous system,brain,other,ganglioglioma c.1919T>A p.V640E 7:140753336-140753336 3
39 COSM150563774 BRAF central nervous system,brain,other,ganglioglioma c.1799T>A p.V600E 7:140753336-140753336 3
40 COSM118787231 BRAF central nervous system,brain,other,ganglioglioma c.1799T>A p.V600E 7:140753336-140753336 3
41 COSM114609379 ATM central nervous system,brain,other,ganglioglioma c.6315G>C p.R2105S 11:108317489-108317489 3
42 COSM88154796 ATM central nervous system,brain,other,ganglioglioma c.6315G>C p.R2105S 11:108317489-108317489 3

Expression for Ganglioglioma

Search GEO for disease gene expression data for Ganglioglioma.

Pathways for Ganglioglioma

GO Terms for Ganglioglioma

Cellular components related to Ganglioglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.73 TSC2 TSC1 TH SYP S100B CHGA
2 terminal bouton GO:0043195 9.33 TH SYP GRIN1
3 neuron projection GO:0043005 9.1 TH SYP MAP2 GRIN1 DCX BRAF
4 TSC1-TSC2 complex GO:0033596 8.96 TSC2 TSC1

Biological processes related to Ganglioglioma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 brain development GO:0007420 9.8 NF1 NES GRIN1 DCX
2 negative regulation of cell proliferation GO:0008285 9.77 TSC2 TSC1 TP53 SMARCB1 NF1
3 heart development GO:0007507 9.76 TSC2 TP53 TH NF1
4 cerebral cortex development GO:0021987 9.58 TSC1 TH NF1
5 cellular response to drug GO:0035690 9.5 TP53 TH BRAF
6 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.48 TP53 MYCN
7 response to salt stress GO:0009651 9.43 TP53 TH
8 negative regulation of neuroblast proliferation GO:0007406 9.26 TP53 NF1
9 negative regulation of mitophagy GO:1901525 9.16 TSC2 TP53
10 visual learning GO:0008542 9.13 NF1 GRIN1 BRAF
11 central nervous system development GO:0007417 8.92 TP53 S100B NES DCX

Sources for Ganglioglioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....